The Three-Decade Long Journey in Heart Failure Drug Development

Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This p...

Full description

Saved in:
Bibliographic Details
Published inHandbook of experimental pharmacology Vol. 243; pp. 1 - 14
Main Authors Lewis, Kelly S., Butler, Javed, Bauersachs, Johann, Sandner, Peter
Format Book Chapter Journal Article
LanguageEnglish
Published Switzerland Springer International Publishing AG 01.01.2017
Springer International Publishing
SeriesHandbook of Experimental Pharmacology
Subjects
Cardiovascular Agents - therapeutic use
Cardiovascular medicine
Clinical Trials as Topic
Drug Discovery
Heart failure
Heart Failure - drug therapy
Heart Failure - epidemiology
Heart Failure - physiopathology
Heart failure statistics
Heart failure trials
HFpEF
HFrEF
Humans
Pharmacology
Physiology
Stroke Volume
Heart failure
Heart failure trials
HFpEF
HFrEF
Heart failure statistics
Online AccessGet full text

Cover

More Information
Summary:Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients.
ISBN:3319596586
9783319596587
ISSN:0171-2004
1865-0325
DOI:10.1007/164_2016_101